Development of a new therapeutics of gestational diabetes by inhibition of the central action of lipid phosphatase

Gestational diabetes increases with the life style changes including high-fat feeding and late marriage, and appropriate treatment against the diabetes is required. Present study demonstrated that a central action of estrogen, which is importantfor maintenance of the pregnancy, plays crucial roles in the control of insulin action and glucose homeostasis in mice. In addition, a lipid phosphatase SHIP2 in hypothalamusaffected feeding behavior and body weight by specifically controlling the insulin action. Thus, we developed new candidate compounds for SHIP2 inhibitors by means of ligand-based drug design. We found that new SHIP2 inhibitors improved insulin resistance and glucose metabolism in diabetic mice. These results indicate that inhibition of SHIP2 appears to be beneficial for the treatment of gestational diabetes